Tumour infiltrating lymphocytes (TIL) are an important prognostic biomarker in triple-negative (TNBC) and HER2-positive breast cancer. Speaking at the San Antonio Breast Cancer Symposium (SABCS), Professor Sherene Loi from the Peter MacCallum Cancer Centre, gave an overview of the evidence for and use of TIL in early-stage and advanced breast cancer. Professor Loi was speaking ...
Professor Sherene Loi: high TIL a robust marker of breast cancer prognosis
By Mardi Chapman
16 Dec 2020